Welcome to our dedicated page for Viemed Healthcare SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viemed Healthcare, Inc. (VMD) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, along with AI-generated summaries to help interpret complex documents. Viemed is incorporated in British Columbia, Canada and files with the SEC under Commission File Number 001-38973, with its common shares listed on NASDAQ under the symbol VMD.
For a company operating as an in-home clinical care provider of post-acute respiratory healthcare equipment and services in the United States, core filings such as the annual report on Form 10-K and quarterly reports on Form 10-Q are central resources. These documents typically contain detailed information on revenue from respiratory equipment and services, operating expenses, cash flows, and risk factors relevant to its non-invasive ventilation, sleep therapy, oxygen therapy, staffing, and related activities.
Viemed also files frequent current reports on Form 8-K to disclose material events. Recent 8-K filings have covered quarterly and year-to-date financial results, the completion of a share repurchase program, the acquisition of Lehan’s Medical Equipment, and amendments to the company’s credit agreement that extend certain term loan commitment expiration dates and provide technical changes. Some 8-K filings also furnish investor presentations and financial supplements used in communications with analysts and investors.
On this page, users can review Form 4 and other insider transaction filings, where available, alongside periodic and current reports. Stock Titan’s AI tools summarize lengthy filings, highlight key sections, and surface items such as changes to credit facilities, capital allocation actions, and updates to financial guidance that Viemed has chosen to disclose. Real-time updates from EDGAR ensure that new Viemed filings appear promptly, while AI-generated insights are designed to make the company’s regulatory record more accessible to both experienced and newer investors.
Viemed Healthcare’s General Counsel, Jeremy Trahan, reported equity award vesting and related share movements in company stock. On January 29, 2026, 10,774 restricted stock units converted into the same number of common shares, while 2,939 shares were withheld by the company to cover taxes at a value of $7.48 per share.
The filing also shows 3,591 cash-settled phantom share units vesting, economically equivalent to common shares and settled in cash with matching share movements. After these transactions, Trahan directly holds 46,492 common shares, plus 10,773 restricted stock units and 3,591 phantom share units as continuing equity interests.
Viemed Healthcare, Inc. Chief Medical Officer and director William Frazier reported equity award vesting and related share transactions. On January 29, 2026, 2,334 Restricted Stock Units converted into 2,334 common shares, and 778 phantom share units converted into 778 common shares, both at an exercise price of $0 per share.
To cover tax obligations from the RSU vesting, 802 common shares were withheld and disposed of at $7.48 per share, based on the closing market price on January 29, 2026. After these transactions and related dispositions, Frazier beneficially owned 73,214 common shares directly.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.
To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.
Viemed Healthcare, Inc. Chief Operating Officer and director William Todd Zehnder reported equity compensation vesting and related tax share dispositions. On January 29, 2026, 26,842 restricted stock units converted into an equal number of common shares, and 8,948 cash-settled phantom share units vested, each economically equivalent to one common share.
The company withheld 11,368 common shares at $7.48 per share and a further 8,948 common shares at the same price to cover tax obligations tied to these awards. After these transactions, Zehnder directly owned 390,309 common shares of Viemed Healthcare.
Viemed Healthcare Chief Medical Officer reports equity award vesting and related share transactions. Director and Chief Medical Officer William Frazier reported the vesting of 3,401 Restricted Stock Units (each equal to one common share) and 850 cash-settled phantom share units on January 21, 2026. After these transactions, he directly owned 71,682 common shares.
To cover tax obligations from the RSU vesting, 1,169 common shares were withheld by the company at a per‑share value of $7.49, and 850 common shares were simultaneously acquired and disposed of in connection with settlement of phantom share units for cash. Following the derivative activity, he held 6,800 Restricted Stock Units and 1,700 phantom share units, which were originally granted on January 21, 2025 and vest in three equal annual installments.
Viemed Healthcare President Michael Moore reported equity award vesting and related share movements. On January 21, 2026, 34,214 Restricted Stock Units (RSUs) were converted into an equal number of common shares, and 8,554 phantom share units under the company’s Phantom Share Unit Plan vested, each economically equivalent to one common share.
To cover taxes from RSU vesting, 9,358 common shares were withheld by Viemed Healthcare at a per share value of $7.49, and 8,554 common shares related to the phantom share settlement were disposed of to the company at the same value. After these transactions, Moore directly held 169,590 common shares, 68,428 RSUs and 17,107 phantom share units, and also had an indirect interest in 1,722,614 common shares held by Moore Faster LLC.
Viemed Healthcare, Inc. Chief Executive Officer and director Hoyt Casey reported equity compensation activity and related share movements. On January 21, 2026, 49,597 Restricted Stock Units and 12,400 phantom share units vested, each unit representing the economic equivalent of one common share. In connection with the RSU vesting, the company withheld 13,565 common shares at $7.49 per share to satisfy tax obligations, and 12,400 common shares tied to phantom units were delivered back to the company for cash settlement.
After these transactions, Casey directly holds 324,582 common shares, along with 99,194 RSUs and 24,798 phantom share units. He also has an indirect holding of 1,984,943 common shares through Elizabeth Rose Homes LLC.
Viemed Healthcare, Inc. insider William Todd Zehnder, the Chief Operating Officer and a director, reported equity compensation transactions on 01/21/2026. He exercised 117,548 Restricted Stock Units (RSUs), each converting into one common share, and his directly held common shares increased as part of this vesting.
To cover related tax obligations from the RSU vesting, the company withheld 35,075 common shares at a per‑share value of $7.49, based on the market closing price on January 21, 2026. The filing also shows vesting and settlement of 8,554 cash‑settled phantom share units, economically equivalent to common shares, which resulted in both an acquisition and disposition of the same number of common shares for cash.
After these transactions, Zehnder directly owned 374,835 common shares, along with 235,094 RSUs and 17,107 phantom share units that remain outstanding and continue to represent future or cash‑settled economic exposure to Viemed common shares.
Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity involving restricted stock units, phantom share units, and common shares on January 21, 2026. A block of 13,317 restricted stock units vested and converted into common shares, with 4,246 of those shares withheld by the company to cover taxes at a per-share value of $7.49, leaving 98,523 common shares directly held after the transactions. In addition, 3,329 cash-settled phantom share units vested under the company’s Phantom Share Unit Plan, which were economically equivalent to common shares and were settled in cash through a matched acquisition and disposition of 3,329 underlying common shares. Following these events, Trae held 26,632 restricted stock units and 6,658 phantom share units, each unit tied to one common share.
Viemed Healthcare Vice President of Sales Cambre Jerome reported equity award activity and related share transactions. On January 21, 2026, 11,719 Restricted Stock Units (RSUs) vested and were settled into an equal number of common shares, consistent with each RSU representing one common share. To cover taxes from this vesting, the issuer withheld 3,827 common shares at a per-share value of $7.49, based on the market closing price for that date.
The filing also shows vesting of 2,930 cash-settled phantom share units granted under Viemed’s Phantom Share Unit Plan, which are economically equivalent to common shares. The settlement is reported as an exchange of phantom shares for the underlying common shares and a simultaneous disposition of those common shares back to the company for cash. After these transactions, Jerome directly beneficially owned 97,824 common shares, as well as 23,436 RSUs and 5,859 phantom share units that remain outstanding.